Recently, the FDA has put forth promising harm reduction programs to reduce morbidity and mortality associated with drug overdoses. The FDA will expand availability and access to overdose reversal products, including naloxone, by supporting accelerated review of products and exploring over-the-counter access. They will also support the development of novel overdose reversal products and fentanyl … Continue reading The FDA is Sending Mixed Messages about Harm Reduction